Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

AI Eye Podcast: GBT Technologies' (OTC: $GTCH) CTO Discusses the Significance of FDA Approval for the qTerm Human Vital Signs Device


Point Roberts, WA and Vancouver, BC - January 27, 2021 ( Newswire) (, a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye, featuring technology company GBT Technologies Inc. (OTCPINK:GTCH).

Listen to today's podcast:

AI Eye Podcast- GBT Technologies (OTC: $GTCH) Discusses Significance of FDA Approval for qTerm Human Vital Signs Device


Hear the AI Eye on Spotify

GBT Technologies Inc. (OTC PINK:GTCH) recently announced that GBT Tokenize Corp, its joint venture, is now seeking approval for its qTerm human vital signs device with the United States Food and Drug Administration (FDA). In an interview with, GBT's CTO, Danny Rittman, explained that the rigour of the FDA approval process was necessary and beneficial to the product.

"We are expecting some improvements and modifications because during the process of the FDA approval - and with their own guidelines and standards - we may definitely need to do some," he said. "That's something we're looking forward to, because that's only going to make the device better, more accurate and more credentialed. The more credentials we get for the device, the better for us. That's the plan."

FDA approval will also grant the qTerm legitimacy in the eyes of consumers, Rittman explained in a recent press release:

"Another aspect is to gain potential customer's confidence and trust in the product's performance and accuracy. We plan to offer the technology for personal, hospital and clinical usage [in] seeking to comply with the industry's standards and regulations."

Rittman clarified however, that approval from the FDA is not essential but rather that the company was pursuing it to expand future market opportunities.

"FDA approval is not a must for qTerm, we voluntarily do this certification in order to bring the device to a clinical level which can open a whole world of possibilities marketing wise (clinics, hospitals, etc...)," he said. "The device can be introduced to the market as is in many other wearables that are not defined as a "medical device", if for ramification only."

In its first release, the qTerm will boast the abilities to measure body temperature, blood oxygen level and heart rate. GBT Tokenize will subsequently add blood pressure to this and these functions will be accompanied by a smartphone app and web application that will keep a history for the user's records, providing a geographical proximity alert and record statistical data about the user's vitals.

"In addition the device measures ambient temperatures to notify the user about an efficient measurement environment for accuracy purposes." Rittman added.

While there are other mobile health detection devices out there, the qTerm is distinguished by its being powered by GBT's AI technology. Rittman indicated in the press release:

"...we believe that its main advantage upon similar products is its Artificial Intelligence technology that offers advanced features like real-time health statistics, analytics, and monitoring."

"The AI will basically collect the data, track it, keep a history and will alert personally, per person in case of abnormalities," he said. "Assuming a person takes, on a daily basis, their blood pressure, oxygen level or heart rate ... the AI engine will notice differences ... and the user is going to get notifications."

From the press release: "Early detection of potential health issues, based on vitals can be crucial and a life saver. Applying for an FDA clearance is a long process but we strongly believe it will bring our technology to the highest standards to be used by hospitals and individuals."

Sam Mowers,

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on visit here or become an Investor Ideas member

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

About GBT Technologies Inc.

GBT Technologies Inc. (OTC PINK: GTCH) ("GBT") ( is a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms. GBT has a portfolio of Intellectual Property that, when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software. GBT's system envisions the creation of a global mesh network. The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. GBT envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.

About - News that Inspires Big Investing Ideas is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.

The podcasts are also available on iTunes, Spotify, Tunein, Stitcher,, iHeartRadio and Google Play Music.

Visit the Podcast page at

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Disclosure: GTCH is a paid for featured AI stock on

Global investors must adhere to regulations of each country. Please read privacy policy:

The AI Eye - Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of

The AI Eye - Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of

Follow us on Twitter

Follow us on Facebook

Follow us on YouTube

Download our Mobile App for iPhone and Android


800 665 0411

Get more tech stocks investor ideas - news, articles, podcasts and stock directories

Buy a technology guest post on